EHA 2024 | First results of the APOLLO trial: ATRA-ATO versus SoC in high-risk acute promyelocytic leukemia
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, presents the first results of the APOLLO trial (NCT0268840), a Phase III randomized study comparing arsenic trioxide (ATO) plus all-trans retinoic acid (ATRA) to the standard of care (SoC) of ATRA and chemotherapy for the treatment of patients with newly diagnosed, high-risk acute promyelocytic leukemia (APL). Despite facing challenges in its recruitment due to the COVID-19 pandemic, the study met its primary endpoint. With the validation of these findings, the ATRA-ATO regimen may present a new SoC for this subgroup of patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
